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Risk of post-discharge venous thromboembolism in patients
with rheumatoid arthritis undergoing knee or hip arthroplasty.
Is prolonged thromboprophylaxis warranted or dangerous?
Venous thromboembolism (VTE)—that is, deep venous
thrombosis (DVT) and pulmonary embolism (PE)—are
common complications after major hip or knee surgery.
Without thromboprophylaxis, the incidence of DVT in
patients undergoing major orthopaedic surgery is more
than 50%, and fatal PE is reported to occur in 1–6% of
these patients.1 These data are based on investigations in
which predominantly osteoarthritis (OA) patients were
studied. Only a few (small) studies were performed in
rheumatoid arthritis (RA) patients: Abernethy reports an
incidence of DVT of more than 70% and overall incidence
of PE of approximately 2% in RA patients who have
undergone a knee arthroplasty,2 and Kelly reports, in his
review,3 an incidence of fatal PE of approximately 1% in
RA patients undergoing total hip replacement and not
receiving thromboprophylaxis (table 1). The risk of devel-
oping DVT seems to be similar for RA patients undergoing
total hip replacement and those undergoing knee replace-
ment surgery.4
Data are conflicting regarding the risk for developing
VTE for RA patients in comparison with OA patients
undergoing major orthopaedic surgery. Similar incidences
of VTE have been reported for OA patients undergoing
major orthopaedic surgery,5 6 whereas one large retrospec-
tive study indicated a possibly lower rate of thromboem-
bolic complications in RA patients (table 1).7 In this inves-
tigation, inhospital morbidity and mortality of 721 RA
patients and 8859 OA patients, who underwent an elective
hip replacement operation, were analysed retrospectively.
The incidence of thromboembolic events was 0.3% in the
RA group versus 1.2% in the OA group (p = 0.07). At first
sight, these very low incidences of VTE are remarkable, but
they are probably related to a very short observation period
and underdiagnosing, by only observing clinical VTE.
Hence, the incidence of VTE seems to be underestimated
in this study.
Altogether, it remains unknown whether there is a
diVerence in VTE risk between RA and OA patients and
obviously, more reliable data should come from (prospec-
tive) investigations with adequate end point assessment.
Development of venous thrombosis during/after
(orthopaedic) surgery
Hypercoagulability, caused by tissue damage and intraop-
erative and postoperative stasis, is a common pathogenic
factor for the development of DVT, in all surgical patients.
Additional pathogenic factors play an important part in
major orthopaedic procedures. The femoral vein is
distorted and kinked during total hip replacement. This
leads to stasis of blood and to vessel wall damage, which
promotes fibrin formation. In addition, it leads to a local
exhaustion of tissue plasminogen activator (t-PA), the acti-
vator of the fibrinolytic system.8 This results in an insuY-
cient suppression of the local fibrin formation that occurs
during the operation.
During total knee arthroplasty, tourniquets are usually
applied to reduce blood loss and this results in stasis of
blood and anoxia in the distal portion of the leg, which also
leads to an exhaustion of endothelial t-PA stores and inad-
equate inhibition of fibrin formation.
Patients who have undergone major orthopaedic surgery
develop swelling in the operated region, partly because of
inflammatory reactions and partly because of wound hae-
matomas, which may result in leg vein compression and
stasis of blood.
The exhaustion of t-PA stores, in addition to local
venous endothelial damage and blood stasis, leads to an
increased perioperative fibrin formation and may explain
the high incidences of VTE in major orthopaedic surgery.
The peak incidence of DVT is observed around the fifth
postoperative day.4 8 9 After the first postoperative week a
second activation of coagulation occurs, as demonstrated
by an increase of thrombin-antithrombin III complexes
and D-dimer, markers of coagulation activation, which
may persist up to six weeks or longer.10 The pathophysi-
ological mechanism for this activation is not known, but it
might be partly attributable to a (relative) immobilisation
of the patient after hospital discharge in addition to the
discontinuation of pharmacological thromboprophylaxis.
Need for thromboprophylaxis during hospitalisation
Obviously, thromboprophylaxis is mandatory in patients
undergoing major orthopaedic surgery and presently, dur-
ing the hospitalisation period, low molecular weight
heparin (LMWH) is the most commonly applied thrombo-
prophylactic agent in the majority of the orthopaedic sur-
gery units in Europe. The evidence for the eYcacy and
safety of LMWH is derived from (large) trials in which
predominantly OA patients were studied. However,
although no conclusions for RA patients could be drawn in
view of the very limited number of RA patients studied,
LMWH is also commonly used in RA patients as
thromboprophylaxis.
Numerous investigations and several meta-analyses have
demonstrated the eYcacy and safety of LMWH in the pre-
vention of postoperative thromboembolic events after
major orthopaedic surgery (table 2).11–13 Several studies
have compared LMWH with unfractionated heparin in
patients undergoing major orthopaedic surgery, indicating
an overall risk reduction of approximately 25% for the
Table 1 Inhospital venous thromboembolism, without thromboprophylaxis, in major orthopaedic surgery patients
Study Patients (n) Operation Patients category
Deep vein
thrombosis (%)
Pulmonary
embolism (%)
Venographically assessed DVT
Salzman and Hirsh*1 — THR not reported 50 1–6
Kelly*3 — THR RA 50 1
Abernethy*2 — TKR RA 70 2
Stringer5 55 THR not reported 56 2
Clinically assessed DVT
White et al7 8 859 721 THR THR OA RA 1.2† 0.3†
DVT=deep venous thrombosis. THR=total hip replacement. RA=rheumatoid arthritis. TKR=total knee replacement. OA=osteoarthritis. *Review. †Clinically appar-
ent deep venous thrombosis and pulmonary embolism.
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development of DVT and an approximately 50% risk
reduction for PE, when comparing LMWH with unfrac-
tionated heparin, without an increase of major bleeding
complications.11 13
However, there is still a considerable rate of symptomless
DVT, approximately 15–20% at the end of the hospital
stay.12
Is post-discharge thromboprophylaxis needed?
Despite this high residual rate of approximately 15–20%
and laboratory evidence of continuing coagulation activa-
tion, there is no consensus whether or not prophylaxis
should be continued after hospital discharge in OA or RA
patients who have undergone major orthopaedic surgery.
Reduction of post-discharge VTE by anticoagulants
should be carefully weighed against risk of bleeding and the
concomitant costs. To date, no conclusive evidence,
particularly for RA patients, is available and presently,
many orthopaedic surgeons in the Netherlands continue
thromboprophylaxis after hospital discharge for six weeks
up to three months, for which oral anticoagulants, mostly
acenocoumarol, are used. This practice is based on one
small scale investigation in which a total of 101 patients, 87
OA patients and 14 RA patients, undergoing elective total
hip replacement, were studied. All patients received oral
anticoagulants as thromboprophylaxis during the hospital
stay, which was stopped at the time of the hospital
discharge. This study indicated a high rate of post-
discharge non-fatal symptomatic PE, which was observed
in three of 55 patients (7%) with negative radionuclide
venography 10 days after the operation.14 The major draw-
back of this investigation is that the applied detection
method, radionuclide venography, is not an adequate
screening test for detecting (symptomless) DVT,which can
only be detected properly by contrast venography.15 Hence,
the PE observed in this investigation might have come from
patients with a false negative radionuclide venography and
therefore, the true post-discharge incidence of PE might be
overestimated.
Recently, a much lower incidence of post-discharge PE
was reported.16 In this large open trial the occurrence of
post-discharge clinically overt VTE in patients not receiv-
ing prolonged prophylaxis was investigated. A total of
almost 2000 patients (predominantly OA), undergoing hip
or knee arthroplasty, were studied and clinically overt VTE
was observed in 40 patients (2%). DVT was detected in 25
patients, non-fatal PE in 14 patients and one patient
suVered from a fatal PE. To date, no data regarding the
incidence of post-discharge VTE in RA patients have been
published.
Thus far, the routine use as well as the duration of post-
discharge anticoagulation with oral anticoagulants has
never been validated adequately and consequently, post-
discharge anticoagulation is not applied by all orthopaedic
surgeons.17
Bleeding risks caused by prolonged (post-discharge)
anticoagulation with oral anticoagulants have never been
resolved properly for major orthopaedic surgery patients.
Investigations in other patient categories (for example,
treatment of VTE) indicate, per treated patient, a major
bleeding risk (requiring hospitalisation) of 1–8% and a
fatal bleeding rate of 0.5–4.8%.18–23 An important point of
consideration, is the additional bleeding risk if a non-
steroidal anti-inflammatory drug (NSAID) is used in com-
bination with oral anticoagulants.24 For instance, the
relative risk for a gastrointestinal bleeding or perforation is
more than six times increased when a NSAID is used in
addition to oral anticoagulants.25 These bleeding risks also
favour withholding prolonged thromboprophylaxis. Addi-
tional arguments are:
(1) the clinical significance of symptomless DVT is not
known, although it is generally accepted, that some will
lead to symptomatic DVT and PE,9 26 27 and others to
the post-thrombotic syndrome28
(2) immobilisation, an important risk factor for the devel-
opment of VTE during hospital stay,29 has only a lim-
ited significance at the time of the hospital discharge,
as most patients are then ambulant
(3) a thromboprophylactic eVect has been suggested for
NSAIDs,30 and therefore, prolonged prophylaxis
would not be required for RA patients as most are
using NSAIDs.
Altogether, it seems that the balance between benefit and
risk for prolonged (post-discharge) anticoagulation, par-
ticularly for RA patients, has not yet been elucidated.
Do aspirin and other NSAIDs have an eVect on
venous thromboembolism?
Aspirin irreversibly inhibits cyclooxygenase by acetylation
whereas other NSAIDs produce a reversible inhibition by
competing, with the substrate arachidonic acid, for the
active site on the enzyme. The major mechanism for the
well established (arterial) anti-thrombotic eVect of aspirin
is mediated through its ability to irreversibly block the syn-
thesis of platelet thromboxane A2.
31
Classically the arterial thrombus is largely composed of
platelets and fibrin and therefore, arterial thrombi are
known as white thrombi. Venous thrombi have a much
richer content of erythrocytes and are therefore known as
red thrombi. Hence, it is conceivable that, from a
pathophysiological point of view, aspirin (and other
NSAIDs), because of their inhibition of platelet aggrega-
tion, have a more pronounced (inhibitory) eVect on the
development of arterial thrombi compared with venous
thrombi.
For NSAIDs also a prophylactic eVect on the develop-
ment of VTE has been hypothesised.
EXPERIMENTAL ANIMAL INVESTIGATIONS
One experimental animal study indicated a moderate,
inhibitory, eVect of NSAIDs on VTE.30 In this investiga-
tion, Doutremepuich and coworkers investigated the effect
of NSAIDs on laser induced venous and arterial thrombo-
sis in a rat model. For several NSAIDs, a significantly
higher number of laser beams was required to induce arte-
rial thrombosis, compared with control (NaCl 0.9%),
Table 2 Inhospital venous thromboembolism, with thromboprophylaxis, in major orthopaedic surgery patients
Study Patients (n) Operation Patients category
Thrombo-
prophylaxis
Deep vein
thrombosis (%)
Pulmonary
embolism (%)
Venographically assessed DVT
Sharrock et al6 436 TKR OA (n=382); RA (n=54) aspirin 42 39 not reported
Nurmohamed et al*11 672 THR not reported LMWH 14 2
Swierstra et al14 101 THR OA (n=87); RA (n=14) OAC 23† 0
Howard et al13 1599 TKR not reported LMWH 32 0.3
Clinically assessed DVT
Leclerc et al16 1141 842 THR TKR not reported LMWH LMWH 1.3 1.8 0.5 0.4
*Meta-analysis. LMWH=low molecular weight heparin. OAC=oral anticoagulants. †Overall incidence. DVT=denotes deep venous thrombosis. THR=denotes total
hip replacement. RA=denotes rheumatoid arthritis. TKR=denotes total knee replacement. OA=denotes osteoarthritis.
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whereas this eVect was not observed for the induction of
venous thrombi. The number of emboli generated from
these thrombi as well as the duration of embolisation were,
for both arterial and venous thrombi, significantly
decreased by NSAIDs compared with control. This
experiment suggests that NSAIDs have a more pro-
nounced inhibitory eVect on the development of arterial
thrombi than on venous thrombus formation and a similar
eVect on arterial and venous emboli.
CLINICAL INVESTIGATIONS
A meta-analysis of earlier venous thromboprophylaxis
trials among surgical and medical patients, in which
antiplatelet agents (primarily aspirin) were investigated as
thromboprophylactic agents, indicated some beneficial
eVect of aspirin against DVT in elective orthopaedic
surgery.32 Thirteen elective orthopaedic surgery trials were
considered for this analysis and encompassed a total of 863
patients. Antiplatelet therapy was administered to 427
patients, whereas there were 436 control patients.DVTwas
detected in 232 control patients (53.2%) and in 160
antiplatelet treated patients (37.5%, 49% odds reduction).
Although the reduction seems substantial, these results
must be interpreted cautiously as most studies that were
included in this meta-analysis, suVered from methodologi-
cal deficiencies, such as an open study design and
inadequate end points.Hence, this meta-analysis cannot be
considered conclusive regarding the eVect of aspirin on the
prevention of VTE.33 A thromboprophylactic eVect on
VTE of NSAIDs, other than aspirin, has never been proved
in recent clinical investigations. This is probably related to
the fact that in most thromboprophylaxis trials NSAIDs
were either stopped, or their use was strongly discouraged
or patients using NSAIDs were excluded. Altogether, there
seems no clinically relevant eVect of aspirin (and other
NSAIDs) in the prevention of venous thromboembolism,
in contrast with the well established eYcacy of aspirin in
preventing arterial thrombosis.27
NSAIDs are used by most RA patients and, to a lesser
extent, by OA patients. They are stopped postoperatively in
the majority of OA patients whereas they are continued,
and still used after hospital discharge, in RA patients.
Therefore, the balance of benefit—that is, reduction of
post-discharge thromboembolism—and risk—that is, in-
duction of bleeding complications—could be diVerent for
RA patients compared with OA patients.
Post-discharge thromboprophylaxis
Recently, four randomised double blind studies investigat-
ing extended prophylaxis with LMWH after hospital
discharge were reported.35–38 The investigations had a com-
parable design involving post-discharge randomisation to
either additional LMWH for a period of up to five weeks,
or placebo. Almost 900 OA patients undergoing total hip
replacement were investigated and large risk reductions of
40–60%, with residual DVT incidences of 4 up to 19%,
during the post-hospitalisation period, were observed
(table 3). There was no increased risk of bleeding compli-
cations or other adverse events in the LMWH groups.
However, only a very limited number of RA patients were
studied (for example, only 1 of 179 patients studied in the
trial of Planes and coworkers,37 had RA) and therefore,
these encouraging results cannot be extrapolated to RA
patients.
In addition, a comparison with oral anticoagulants, the
commonly applied drug for prolonged thromboprophylaxis
in the Netherlands, is lacking and finally, the optimal dura-
tion of post-discharge thromboprophylaxis is not known.
Therefore, extended pharmacological prophylaxis of
VTE in RA patients, undergoing major orthopaedic inter-
ventions, continues to be a serious matter of debate, which
only can be solved by an appropriate trial.
Conclusions
VTE is an important postoperative complication of major
orthopaedic surgery in OA and RA patients, albeit that, in
RA patients, the risk for developing VTE might be lower
than in OA patients. LMWH eVectively reduces the
incidence of VTE during hospital stay in OA patients.
LMWH is also commonly used as postoperative thrombo-
prophylaxis in RA patients but this has never been
validated.
The incidence of post-discharge VTE in OA patients
seems to be substantial, and there is accumulating evidence
that this can be safely lowered by prolonged administration
of LMWH.
No data are available regarding the magnitude of
post-discharge VTE in RA patients. The risk of RA
patients might be diVerent in comparison with OA patients
in view of (a) an a priori possibly lower incidence of VTE
during hospital stay and (b) post-discharge use of NSAIDs,
which is accompanied by an increased bleeding risk if they
are used in combination with anticoagulants. Hence, the
balance of benefit and risk might be quite diVerent for RA
patients in comparison with OA patients.
Clearly there is a need for a randomised placebo
controlled trial with LMWH and objective end point
assessment (that is, venography) that investigates this topic.
Only after the results of such an investigation become
available, can definitive recommendations regarding ex-
tended thromboprophylaxis for RA patients undergoing
major orthopaedic surgery be given—that is, whether it is
warranted or dangerous.
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